David Liu (Casey Atkins Photography courtesy Broad Institute)

New small mol­e­cule play­er with roots in David Li­u's lab col­lects an­oth­er $78M to fu­el search for ex­osites

Af­ter work­ing in CRISPR and then the mi­cro­bio­me field, Michael Bruce de­cid­ed back in 2019 that it was time for a change.

“A lot of peo­ple joked and asked whether I was go­ing to go and work for an RNA com­pa­ny, which, giv­en all that’s hap­pened over the last year or two, maybe that would have been a good idea,” he joked.

In­stead, he dove in­to a space he hopes will be­come just as large: cre­at­ing small mol­e­cules that tar­get rarely pur­sued bind­ing sites called ex­osites. And on Tues­day, his com­pa­ny Exo Ther­a­peu­tics un­veiled a $78 mil­lion Se­ries B round to fu­el its dash for the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.